Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totalling 619,400 shares, a growth of 747.3% from the June 30th total of 73,100 shares. Based on an average daily volume of 2,640,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 6.0% of the company’s stock are short sold.
Conduit Pharmaceuticals Trading Down 1.5 %
Shares of CDT traded down $0.00 on Friday, reaching $0.24. The company’s stock had a trading volume of 698,643 shares, compared to its average volume of 1,238,873. Conduit Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $25.00. The firm has a fifty day moving average of $1.60 and a 200-day moving average of $2.61.
Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter.
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Articles
- Five stocks we like better than Conduit Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Evaluate a Stock Before Buying
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to Invest in Insurance Companies: A Guide
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.